Table 2.
Patient Clinical/Laboratory Characteristics
| Characteristics | N | AMC-FAS Population |
|---|---|---|
| Post-bronchodilator FVC (L) | 417 | 3.13 (0.88) |
| Post-bronchodilator FEV1 (L) | 417 | 1.70 (0.65) |
| Post-bronchodilator FEV1/FVC (%) | 417 | 54.1 (12.7) |
| FEV1 (% predicted) | 417 | 65.8 (21.1) |
| Inspiratory capacity (L), mean (SD) [median] | 417 | 2.17 (0.58) [2.2] |
| GOLD stage, n (%) | 417 | |
| I | 123 (29.5) | |
| II | 183 (43.9) | |
| III | 98 (23.5) | |
| IV | 13 (3.1) | |
| Presence of emphysema by CT, n (%) | 416 | |
| No | 47 (11.3) | |
| Yes | 369 (88.7) | |
| Evaluation of emphysema by CT, n (%) | 411 | |
| None (0%) | 46 (11.2) | |
| Moderate (<50%) | 283 (68.9) | |
| Severe (≥50%) | 82 (20.0) | |
| Pulmonary diffusing capacity disorder, n (%) | 414 | |
| No | 143 (34.5) | |
| Yes | 271 (65.5) | |
| Eosinophils ratio (%) | 278 | 3.6 (2.4) |
| Peripheral eosinophils count (cells/µL) | 278 | 221.4 (156.4) |
| FeNO measurement (ppb) | 225 | 25.7 (20.3) |
| At least one complication/comorbidity | 417 | 321 (77.0) |
| Hypertension | 164 (39.3) | |
| Asthma | 131 (31.4) | |
| Diabetes | 59 (14.1) | |
| Ischemic heart disease | 40 (9.6) | |
| Gastroesophageal reflux disease | 40 (9.6) | |
| Osteoporosis | 15 (3.6) | |
| Heart failure | 14 (3.4) | |
| Depression/anxiety | 13 (3.1) |
Note: Data are shown as mean (SD) unless otherwise stated.
Abbreviations: AMC-FAS, activity monitor classification-full analysis set; CT, computed tomography; FeNO, fractional concentration of exhaled nitric oxide; FEV1, forced expired volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation.